Ribo Submits CTA in the EU for P-I Trial of Dual-Targeting siRNA SR122 to Treat Dyslipidemia

Shots: Suzhou Ribo Life Science & its subsidiary Ribocure Pharmaceuticals have submitted a P-I CTA in the EU for SR122, a dual GalNAc-conjugated siRNA, to treat dyslipidemia, incl. severe hypertriglyceridemia (sHTG) & mixed dyslipidemia The randomized, placebo-controlled P-I trial will evaluate the safety, tolerability, PK & PD of SC SR122 in healthy participants, providing the first human evaluation of the dual-targeting approach SR122 simultaneously targets ApoC3 & PCSK9 to address both triglyceride-rich lipoproteins & LDL-C; Ribo is also advancing P-II studies of its ApoC3-targeting siRNA, RBD5044, in Europe & China Ref: PR Newswire  |   Image: Ribo  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Ribo Submits CTA in the EU for P-I Trial of Dual-Targeting siRNA SR122 to Treat Dyslipidemia appeared first on PharmaShots.